John Parker, MD
Ophthalmology · Vestavia, ALNPI 1114033016
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Glaukos Corporation at 46.4% of the total. Reporting peaked in 2019 at $6,528 and has fallen 84.2% since, to $1,031 in 2025. Among ophthalmology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $109.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$9K
- Avedro Inc.$6K
- Eyevance Pharmaceuticals LLC$674
- Alcon$628
- AbbVie$502
- Carl Zeiss Meditec USA, Inc.$426
- plus $2K from 24 others
What the payments were for
- Consulting fees$10,00052%
- Speaking & faculty fees$2,00010%
- Food & beverage$7,28438%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KXL System$3,415
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$1,000
- Photrexa$839
- Clareon$358
- CE-marked KXLA system$313
- Tobradex ST$275
- LUMERA 700$226
- XEN$226
- Photrexa Viscous and Photrexa$187
- iDose$132
- Zerviate$125
- XEN GLAUCOMA TREATMENT SYSTEM$119
- INFUSE$110
How this compares
$19,329 in reported general payments places this provider in the 95th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 36 | $1,270,084 |
| Fluorometholone | 828 | $70,257 |
| Prednisolone Acetate | 898 | $49,779 |
| RestasisCyclosporine | 50 | $46,944 |
| LotemaxLoteprednol Etabonate | 115 | $42,646 |
| Cyclosporine | 43 | $26,671 |
| XiidraLifitegrast | 20 | $19,269 |
| ValacyclovirValacyclovir Hcl | 251 | $18,584 |
| LumiganBimatoprost | 31 | $15,256 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 653 | $14,256 |
| Latanoprost | 808 | $14,090 |
| VyzultaLatanoprostene Bunod | 36 | $12,875 |
| Loteprednol Etabonate | 64 | $11,939 |
| MoxifloxacinMoxifloxacin Hcl | 311 | $10,311 |
| MieboPerfluorohexyloctane/Pf | 12 | $9,044 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $176 | $1,270,08436 claims |
| AbbVieRestasis, Lumigan, Alphagan P | $502 | $66,32297 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Loteprednol Etabonate | $38 | $54,585179 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $154 | $41,18868 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $152 | $6,21820 claims |
| AlconSimbrinza | $628 | $2,60313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Vestavia
- Young ChoiVestavia$5K
- Bret FisherHomewood$545K
- Caroline WatsonHuntsville$292K
- Ronald GrossFairhope$143K
- Kristin BainsBirmingham$40K
- Sebastian HeersinkDothan$33K
- Lindsay RhodesBirmingham$18K
- Timothy JohnsonTuscaloosa$15K
- James LewisBirmingham$15K
- In ShinMontgomery$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.